BFRGWHIGH SIGNALFINANCIAL10-K

BFRGW faces severe liquidity deterioration with cash declining 60% to $2.2M and stockholders' equity falling to $2.1M, triggering Nasdaq delisting warnings for failing to maintain the $2.5M minimum equity requirement.

The company is in financial distress with stockholders' equity below Nasdaq's minimum listing requirements, forcing them to submit a compliance plan with an extension deadline of February 2026. The dramatic cash burn and equity erosion, combined with declining gross margins despite revenue growth, indicates urgent funding needs and potential going concern issues.

Comparing 2026-03-19 vs 2025-03-14View on EDGAR →
FINANCIAL ANALYSIS

BFRGW experienced severe financial deterioration with cash plummeting 60% to $2.2M and stockholders' equity collapsing 57% to $2.1M, while total assets declined 49%. Despite revenue increasing 80% to $117K, gross profit fell 63% indicating margin compression, and the company reduced R&D spending by 19% likely due to cash constraints. The overall picture signals a company in financial distress burning through cash rapidly with deteriorating profitability metrics and insufficient equity to maintain exchange listing requirements.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+79.5%
$65K$117K

Strong top-line growth of 79.5% — accelerating demand or successful expansion into new markets.

Interest Expense
P&L
-77.2%
$347K$79K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Gross Profit
P&L
-63.4%
$60K$22K

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Cash & Equivalents
Balance Sheet
-59.8%
$5.4M$2.2M

Cash declined 59.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Stockholders Equity
Balance Sheet
-57%
$5.0M$2.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-53.4%
$5.5M$2.6M

Current assets declined 53.4% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-49.4%
$5.6M$2.8M

Total assets contracted 49.4% — asset sales, write-downs, or balance sheet optimization underway.

R&D Expense
P&L
-19%
$2.2M$1.8M

R&D spending cut 19% — could signal cost discipline or concerning reduction in innovation investment.

Total Liabilities
Balance Sheet
+14.3%
$588K$672K

Liabilities increased 14.3% — monitor debt-to-equity ratio and interest coverage.

Current Liabilities
Balance Sheet
+14.3%
$588K$672K

Current liabilities rose 14.3% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-14
ADDED
The forward-looking statements in this report are largely based upon management s current expectations and beliefs about future events and trends affecting our business, which management believes are reasonable.
A major challenge in developing new therapeutics is efficiently integrating the complex, high-dimensional data generated at each stage of development to help de-risk subsequent stages of the process.
We use AI/ML to advance medicines for both internal and external projects.
4 Recent Developments As previously reported, on August 21, 2025, the Company received written notice from The Nasdaq Stock Market LLC ( Nasdaq ) that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders equity for continued listing (the Stockholders Equity Requirement ).
The Company submitted a plan to regain compliance with the Stockholders Equity Requirement (the Plan ) to Nasdaq on September 30, 2025.
+7 more — sign up free →
REMOVED
The forward-looking statements in this report are based upon management s current expectations and beliefs, which management believes are reasonable.
was incorporated in the State of Delaware on August 25, 2017.
A major part of the difficulty in developing new therapeutics is efficient integration of complex and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process.
We use artificial intelligence and machine learning to advance medicines for both internal and external projects.
4 Recent Developments In February 2025, we announced our entry into a collaboration agreement with Eleison Pharmaceuticals Inc.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →